Xiaopeng Tian
Overview
Explore the profile of Xiaopeng Tian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Y, Zou Q, Zhao B, Su N, Li Z, Wang X, et al.
Cell Rep Med
. 2024 Nov;
5(12):101833.
PMID: 39615484
Treatment options for patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) after failure of platinum-based therapy are limited. In this phase 2 trial, 40 patients with RM-NPC who failed platinum-based...
2.
Kong P, Xu T, Liu P, Tian X
Sci Rep
. 2024 Sep;
14(1):22504.
PMID: 39341992
The correlation between diverticular disease of the intestine and cirrhosis is well-established, however, the presence of a genetic causal link between the two conditions remains uncertain. The study employed a...
3.
Zhang Y, Deng Y, Zou Q, Jing B, Cai P, Tian X, et al.
Cell Rep Med
. 2024 May;
5(5):101551.
PMID: 38697104
Accurate diagnosis and prognosis prediction are conducive to early intervention and improvement of medical care for natural killer/T cell lymphoma (NKTCL). Artificial intelligence (AI)-based systems are developed based on nasopharynx...
4.
Hong J, Zhu Z, Cui L, Wang Z, Hao Y, Tian X, et al.
J Mater Chem B
. 2024 Feb;
12(9):2354-2363.
PMID: 38344940
Hematopoietic stem cell (HSC) expansion offers a key strategy to address the source limitation and donor shortages of HSCs for the treatment of various blood disorders. Specific remodeling of the...
5.
Su N, Fang Y, Chen X, Chen X, Xia Z, Huang H, et al.
Blood Sci
. 2023 Nov;
5(4):249-257.
PMID: 37941919
T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive non-Hodgkin lymphoma with a poor prognosis. P21-activated kinase (PAK) is a component of the gene expression-based classifier that can predict the prognosis...
6.
Fang Y, Su N, Zou Q, Cao Y, Xia Y, Tang L, et al.
BMC Med
. 2023 Nov;
21(1):423.
PMID: 37936166
Background: Treatment options beyond the first-line setting for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) are limited. The role of the multitarget tyrosine kinase inhibitor anlotinib in RM-NPC is unclear. Methods:...
7.
Yuan H, Su H, Wu C, Ji Y, Zhou L, Wang L, et al.
Front Cell Dev Biol
. 2023 Oct;
11:1280682.
PMID: 37900272
The large-scale production of human pluripotent stem cells (hPSCs), including both embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs), shows potential for advancing the translational realization of hPSC...
8.
Ma R, You F, Tian S, Zhang T, Tian X, Xiang S, et al.
Eur J Haematol
. 2023 Sep;
112(1):64-74.
PMID: 37671595
Objectives: Despite the great success of CD19 CAR-T cell therapy, its clinical efficacy has been greatly hampered by the high relapse rate. In this study, we designed and compared four...
9.
Jiang D, Huang H, Qin H, Tang K, Shi X, Zhu T, et al.
Nat Commun
. 2023 Jun;
14(1):3642.
PMID: 37339964
BCMA-targeting chimeric antigen receptor (CAR) T cell therapy demonstrates impressive clinical response in multiple myeloma (MM). However, some patients with BCMA-deficient tumours cannot benefit from this therapy, and others can...
10.
Tian X, Zhang R, Qin H, Shi X, Qi W, Jiang D, et al.
Cent Eur J Immunol
. 2023 May;
48(1):1-13.
PMID: 37206593
Introduction: Chimeric antigen receptor (CAR)-NK cells are considered safer than CAR-T cells due to their short lifetime and production of lower toxicity cytokines. By virtue of unlimited proliferative ability in...